MNOV vs MNPR

MediciNova, Inc. vs Monopar Therapeutics Inc. — Valuation Comparison 2026

MNOV

Biotechnology
MediciNova, Inc.
Quality
6.2
out of 10
Value Trap
45
WARN
Price
$1.37
Last close
Models
9/13
Active
VS

MNPR

Biotechnology
Monopar Therapeutics Inc.
Quality
4.3
out of 10
Value Trap
6
SAFE
Price
$64.43
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType MNOV Fair ValueMNOV Upside MNPR Fair ValueMNPR Upside
Bayesian DCF Intrinsic $0.67 -51.1% $21.57 -66.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.04 -97.1% $6.18 -90.4%
Dynamic NAV Asset-Based $1.33 -3.2% $25.99 -59.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MNOV vs MNPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MNOV vs MNPR — Which Stock Is More Undervalued?

MNOV scores higher with a 6.2/10 quality rating vs MNPR's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MediciNova, Inc. (MNOV) and Monopar Therapeutics Inc. (MNPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MNOV currently trades at $1.37 with a QOC of 6.2/10, while MNPR trades at $64.43 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).